Uniqure N.V. (QURE) |
|
40.87 -0.82 (-1.97%)
|
08-14 16:00 |
|
Open: |
41.37 |
Pre. Close: |
41.69 |
|
High:
|
41.37 |
Low:
|
40.15 |
|
Volume:
|
176,827 |
Market Cap:
|
1,817M |
|
|
|
|
uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
41.418 - 41.637 |
41.637 - 41.822 |
|
Low:
|
39.636 - 39.882 |
39.882 - 40.091 |
|
Close:
|
40.463 - 40.884 |
40.884 - 41.242 |
|
Technical analysis |
as of: 2020-08-14 4:33:42 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 51.00 One year: 56.18 |
| Support: |
Support1: 36.49 Support2: 30.36 |
| Resistance: |
Resistance1: 43.66 Resistance2: 48.10 |
| Pivot: |
41.02  |
| Moving Average: |
MA(5): 41.22 MA(20): 41.23
MA(100): 53.16 MA(250): 54.34 |
| MACD: |
MACD(12,26): -1.81 Signal(9): -2.40 |
| Stochastic oscillator: |
%K(14,3): 70.63 %D(3): 68.65 |
| RSI: |
RSI(14): 39.65 |
| 52-week: |
High: 76.69 Low: 36.20 Change(%): -28.1 |
| Average Vol(K): |
3-Month: 59648 10-Days: 28279 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.QURE has closed above bottom band by 47.0%. Bollinger Bands are 62.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to QURE's normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 14 Aug 2020
Aug 14, 2020 - Foresite Capital Management IV, LLC Buys Keros Therapeutics Inc, Fulcrum Therapeutics Inc, Kura Oncology Inc, Sells Insmed Inc, MyoKardia Inc, Cytokinetics Inc - GuruFocus.com
Fri, 14 Aug 2020
Estimating Price Trends For uniQure N.V. (NASDAQ: QURE) - The Comet Reports
Fri, 31 Jul 2020
Uniqure (NASDAQ:QURE) Posts Earnings Results, Misses Expectations By $0.31 EPS - MarketBeat
Fri, 31 Jul 2020
Mizuho Securities Stick to Their Hold Rating for uniQure N.V. - Investing.com
Thu, 30 Jul 2020
UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Thu, 30 Jul 2020
A Quick Investment Idea On uniQure - Seeking Alpha
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: Nasdaq Global Select |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
44 |
| Shares Float (M) |
34 |
|
% Held by Insiders
|
7.80 |
|
% Held by Institutions
|
95.93 |
|
Shares Short (K)
|
3,710 |
|
Shares Short P. Month (K)
|
4,500 |
Stock Financials |
|
EPS
|
-2.990 |
|
EPS Est This Year
|
-2.970 |
|
EPS Est Next Year
|
-2.650 |
|
Book Value (p.s.)
|
6.670 |
|
Profit Margin
|
|
|
Operating Margin
|
-2049.91 |
|
Return on Assets (ttm)
|
-23.4 |
|
Return on Equity (ttm)
|
-55.0 |
|
Qtrly Rev. Growth
|
-90.8 |
|
Gross Profit (p.s.)
|
-1.974 |
|
Sales Per Share
|
0.141 |
|
EBITDA (p.s.)
|
-2.737 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-105 |
|
Levered Free Cash Flow (M)
|
-67 |
Stock Valuations |
|
PE Ratio
|
-13.67 |
|
PEG Ratio
|
|
|
Price to Book value
|
6.13 |
|
Price to Sales
|
289.69 |
|
Price to Cash Flow
|
-17.21 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
